TKI first-line therapy Molecular responses continue to deepen with extended treatment duration, reaching 60% major molecular ...

"Our significant showcase at ASH this year reflects Parexel’s specialized scientific and medical expertise in hematology and our commitment to partnering with leading biopharma sponsors to advance ...

Poster presentations highlight AI-driven CD histopathology grading technology; morbidity and financial burden of idiopathic multicentric CD (iMCD); ...

Youngstown State University’s Sokolov Honors College recently hosted its second annual Pre-Health Research Symposium.

Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including hemogl ...

BGB-11417-202 ( NCT05479994) is an open-label, phase 2, and a potential registrational study evaluating the efficacy and safety of sonrotoclax in 100 heavily pretreated patients with R/R CLL/SLL. At a ...

A new national study shows for the first time that people exposed to Agent Orange face a higher risk of developing ...

The CVCT Forum is an annual, invite-only workshop that aims to cultivate a multi-stakeholder exchange to enhance clinical trials, streamline regulatory approval processes, and facilitate the ...

CTO1681 is an oral, small molecule immune modulator that uses a novel approach to prevent and mitigate both inflammation in the tumor microenvironment as well as toxicity frequently seen with lymphoma ...

The concluding day featured a conference-wide poster presentation session, where over 80 participants presented their research across diverse areas of management ...

Amazon Prime Video has recently released a new poster for Spider-Noir, it's upcoming series with Nicholas Cage and here, ...

At the recently enrolled 160 mg dose level, preliminary findings show patients achieving early blast clearance with MRD-negativity and formal responses in the first few weeks of treatment (not ...